# US 2024/0197706 A1 · Methods of improving the pharmacokinetics of migalastat

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197706 A1
- Document ID: US20240197706A1
- Status: Published application
- Kind: A1
- Application number: 18/315,928
- Filed: 2023-05-11
- Published: 2024-06-20
- Earliest claimed: 2022-12-13
- Assignees: Amicus Therapeutics, Inc.
- Applicants: Amicus Therapeutics, Inc.
- Inventors: Franklin Johnson
- Web page: https://patentgrep.com/patent/US20240197706A1

## CPC

- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61K 31/522: having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided are methods of improving the pharmacokinetics of migalastat by limiting caffeine intake during migalastat therapy.

## Claims

### Claim 1

A method of increasing migalastat bioavailability, the method comprising orally administering to a patient a formulation comprising a therapeutically effective dose of migalastat or a salt thereof, wherein the patient does not consume caffeine within about 2 hours of administering the formulation comprising migalastat or a salt thereof and wherein the patient consumes fruit juice without pulp within about 2 hours of administering the formulation comprising migalastat or a salt thereof.

### Claim 2 (depends on 1)

The method of claim 1, further comprising administering caffeine to the patient at least about 2 hours prior to administering the formulation comprising migalastat or a salt thereof.

### Claim 3 (depends on 1)

The method of claim 1, further comprising administering caffeine to the patient at least about 2 hours after administering the formulation comprising migalastat or a salt thereof.

### Claim 4 (depends on 1)

The method of claim 1, wherein the patient does not consume caffeine within 2 hours of administering the formulation comprising migalastat or a salt thereof to avoid a decrease in AUC and Cmax for migalastat of about 57% and about 60%, respectively.

### Claim 5 (depends on 1)

The method of claim 1, wherein the patient fasts for at least about 2 hours prior to administering the formulation comprising migalastat or a salt thereof and for at least about 2 hours after administering the formulation comprising migalastat or a salt thereof.

### Claim 6 (depends on 1)

The method of claim 1, wherein the patient does not consume caffeine for at least about 3 hours prior to administering the formulation comprising migalastat or a salt thereof and for at least about 2 hours after administering the formulation comprising migalastat or a salt thereof.

### Claim 7 (depends on 1)

The method of claim 1, wherein the patient does not consume caffeine within 3 hours of administering the formulation comprising migalastat or a salt thereof.

### Claim 8 (depends on 1)

The method of claim 1, wherein the therapeutically effective dose of migalastat or a salt thereof is in a range of from about 100 mg to about 150 mg every other day.

### Claim 9 (depends on 1)

The method of claim 1, wherein the therapeutically effective dose of migalastat or a salt thereof is about 123 mg free base equivalent (FBE) every other day.

### Claim 10 (depends on 1)

The method of claim 1, wherein the therapeutically effective dose of migalastat or a salt thereof is about 150 mg of migalastat hydrochloride every other day.

### Claim 11

A method of treatment of Fabry disease in a human patient in need thereof, the method comprising orally administering to the patient a formulation comprising a therapeutically effective dose of migalastat or a salt thereof, wherein the patient does not consume caffeine within 2 hours of administering the formulation comprising migalastat or a salt thereof and wherein the patient consumes fruit juice without pulp within about 2 hours of administering the formulation comprising migalastat or a salt thereof.

### Claim 12 (depends on 11)

The method of claim 11, further comprising administering caffeine to the patient at least about 2 hours prior to administering the formulation comprising migalastat or a salt thereof.

### Claim 13 (depends on 11)

The method of claim 11, further comprising administering caffeine to the patient at least about 2 hours after administering the formulation comprising migalastat or a salt thereof.

### Claim 14 (depends on 11)

The method of claim 11, wherein the patient does not consume caffeine within 2 hours of administering the formulation comprising migalastat or a salt thereof to avoid a decrease in AUC and Cmax for migalastat of about 57% and about 60%, respectively.

### Claim 15 (depends on 11)

The method of claim 11, wherein the patient fasts for at least about 2 hours prior to administering the formulation comprising migalastat or a salt thereof and for at least about 2 hours after administering the formulation comprising migalastat or a salt thereof.

### Claim 16 (depends on 11)

The method of claim 11, wherein the patient does not consume caffeine for at least about 3 hours prior to administering the formulation comprising migalastat or a salt thereof and for at least about 2 hours after administering the formulation comprising migalastat or a salt thereof.

### Claim 17 (depends on 11)

The method of claim 11, wherein the patient does not consume caffeine within 3 hours of administering the formulation comprising migalastat or a salt thereof.

### Claim 18 (depends on 11)

The method of claim 11, wherein the therapeutically effective dose of migalastat or a salt thereof is in a range of from about 100 mg to about 150 mg every other day.

### Claim 19 (depends on 11)

The method of claim 11, wherein the therapeutically effective dose of migalastat or a salt thereof is about 123 mg free base equivalent (FBE) every other day.

### Claim 20 (depends on 11)

The method of claim 11, wherein the therapeutically effective dose of migalastat or a salt thereof is about 150 mg of migalastat hydrochloride every other day.
